Type 2 diabetes mellitus with other diabetic neurological complication
ICD-10 E11.49 is a billable code used to indicate a diagnosis of type 2 diabetes mellitus with other diabetic neurological complication.
E11.49 refers to Type 2 diabetes mellitus characterized by the presence of other diabetic neurological complications. This condition arises when prolonged hyperglycemia leads to nerve damage, resulting in various neurological symptoms. Patients may experience peripheral neuropathy, autonomic neuropathy, or other forms of nerve dysfunction. Symptoms can include pain, tingling, numbness in extremities, and issues with autonomic functions such as digestion and heart rate regulation. Management of E11.49 typically involves controlling blood glucose levels through lifestyle modifications, oral hypoglycemic agents, and possibly insulin therapy. Regular monitoring of HbA1c levels is crucial, as it reflects long-term glucose control and helps in assessing the risk of complications. The presence of neurological complications necessitates a multidisciplinary approach, often involving endocrinologists, neurologists, and primary care providers to optimize patient outcomes.
Detailed records of diabetes management, including HbA1c levels and treatment plans.
Patients presenting with uncontrolled diabetes and neurological symptoms.
Ensure that all complications are documented and linked to diabetes for accurate coding.
Comprehensive neurological assessments and symptom descriptions.
Patients with neuropathic pain or autonomic dysfunction related to diabetes.
Document the relationship between neurological findings and diabetes to support coding.
Used for follow-up visits for diabetes management with neurological complications.
Document the patient's diabetes management plan and neurological symptoms.
Endocrinologists should ensure comprehensive documentation of both diabetes and neurological assessments.
Common neurological complications include peripheral neuropathy, autonomic neuropathy, and diabetic mononeuropathy, which can lead to symptoms such as pain, numbness, and gastrointestinal issues.
HbA1c levels should be monitored at least twice a year for patients meeting treatment goals and quarterly for those whose therapy has changed or who are not meeting goals.
